Argenx
ARGX
#421
Rank
C$77.56 B
Marketcap
C$1,245
Share price
-1.62%
Change (1 day)
44.07%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

Revenue for Argenx (ARGX)

Revenue in 2025 (TTM): C$5.05 Billion

According to Argenx 's latest financial reports the company's current revenue (TTM ) is C$4.98 Billion. In 2024 the company made a revenue of C$3.14 Billion an increase over the revenue in the year 2023 that were of C$1.62 Billion. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.

Revenue history for Argenx from 2013 to 2025

Annual revenue

Year Revenue Change
2025 (TTM) C$5.05 B60.87%
2024 C$3.14 B93.23%
2023 C$1.62 B191.82%
2022 C$0.55 B
2019 C$0.11 B188.33%
2018 C$39.66 M-37.16%
2017 C$63.11 M174.76%
2016 C$22.97 M100.4%
2015 C$11.46 M71.15%
2014 C$6.69 M26.88%
2013 C$5.27 M